https://www.biospace.com/aim-immunotech-reschedules-investor-conference-call-to-january-21-2021-at-11am-etaim-to-discuss-amp-511-trial-which-includes-covid-19-induced-chronic-fatigue-long-hauler-patients-and-other-upcoming-milestones
AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has rescheduled its investor conference call for 11:00 a.m. Eastern Time on Thursday, January...
aim immunotechinvestor conferencereschedulescalljanuary
https://www.finanznachrichten.de/nachrichten-2026-02/67627077-aim-immunotech-inc-aim-immunotech-reports-positive-year-end-interim-clinical-progress-from-phase-2-study-evaluating-ampligen-rintatolimod-in-combi-399.htm
OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today reported positive data in a year-end...
aim immunotechyear endincreportspositive
https://www.pharmaceutical-technology.com/data-insights/ampligen-aim-immunotech-net-present-value/
Ampligen is an oligonucleotide commercialized by AIM ImmunoTech, with a leading Phase III program in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis).
net present valuerisk adjustedcurrentvaluation
https://www.home.saxo/nl-be/markets/stocks/aim-xase
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and...
aim immunotechsaxo bankincaandeel